Compare MBLY & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBLY | HRMY |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2022 | 2020 |
| Metric | MBLY | HRMY |
|---|---|---|
| Price | $8.80 | $38.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | $14.13 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 6.7M | 827.7K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.43 | 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | ★ $1,894,000,000.00 | $868,453,000.00 |
| Revenue This Year | $4.91 | $19.75 |
| Revenue Next Year | $13.94 | $12.88 |
| P/E Ratio | ★ N/A | $20.73 |
| Revenue Growth | 14.51 | ★ 21.51 |
| 52 Week Low | $6.47 | $25.52 |
| 52 Week High | $15.81 | $40.87 |
| Indicator | MBLY | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 59.31 |
| Support Level | $8.43 | $34.87 |
| Resistance Level | $9.62 | $39.24 |
| Average True Range (ATR) | 0.32 | 1.28 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 58.08 | 77.04 |
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.